March 10, 2020

POINT Biopharma and SCINTOMICS Announce License Agreement

March 10, 2020 - TORONTO  and MUNICH, Germany - POINT Biopharma Inc. today announced that it has entered into an agreement  with SCINTOMICS GmbH for the exclusive use and development of a family  of more than seventy patented next generation PSMA radioligands for  targeted radiotherapy of prostate cancer. Under the terms of the  agreement, POINT has acquired both North American and broad  international rights to the compounds. SCINTOMICS is eligible to receive  milestone payments and royalties over the life of the collaboration.

The announcement of this acquisition complements POINT Biopharma’s PNT 2002 clinical program set to begin in 2020.

According to Michael Gottlieb, POINT Biopharma’s Chief Commercial Officer, “The breadth of this acquisition provides POINT with a clear strategic pathway of patient focused differentiation. POINT is committed to novel treatments and continued innovation of radiopharmaceutical assets.”

Joe McCann, POINT Biopharma CEO adds, “We are excited to bring these compounds to patients. We anticipate commencement of a phase 1/2 clinical program in 2021.”

Saskia Kropf, SCINTOMICS CEO stated, “We  are delighted that in POINT Biopharma we have found an excellent  partner for the clinical development of this unique targeting  technology. We are certain that in the experienced leadership team from  North America and Europe, POINT is well equipped to make this innovative  radioligand therapy rapidly accessible to prostate cancer patients."

Dr.  Vikas Prasad, (Vice Chair and Senior Physician Department of Nuclear  Medicine University Hospital of Ulm Germany) a scientific advisor to  POINT Biopharma adds, “Radiomolecular compounds for prostate cancer  diagnosis and treatment have been used in Germany for many years with  much success. They are positioned to revolutionize the global treatment  landscape for patients around the world.”

About Scintomics GmbH  

Scintomics,  a privately held company based in Fuerstenfeldbruck/Munich, is  committed to targeted theranostics and corresponding radiopharmaceutical  technologies. Its strong focus towards personalized cancer care is  reflected by an exceptional and continuous growing portfolio of  functional diagnostics and radiotherapeutics and the clinical  development of theranostics through subsidiaries, joint ventures and  alliances.